Full Text:   <304>

Summary:  <161>

Suppl. Mater.: 

CLC number: 

On-line Access: 2023-12-08

Received: 2023-04-10

Revision Accepted: 2023-09-05

Crosschecked: 2023-12-12

Cited: 0

Clicked: 435

Citations:  Bibtex RefMan EndNote GB/T7714

 ORCID:

Fangfang GENG

https://orcid.org/0000-0001-5637-304X

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2023 Vol.24 No.12 P.1159-1164

http://doi.org/10.1631/jzus.B2300232


Typical hemophagocytic syndrome associated with cytomegalovirus infection in an immunocompetent patient: a case report and literature review


Author(s):  Fangfang GENG, Meifang YANG, Xuan ZHANG, Hong ZHAO, De ZHOU, Jianhua HU

Affiliation(s):  State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Department of Infectious Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; more

Corresponding email(s):   hjianhua0825@zju.edu.cn

Key Words:  Cytomegalovirus infection, hemophagocytic lymphohistiocytosis, ruxolitinib, immunocompetent


Fangfang GENG, Meifang YANG, Xuan ZHANG, Hong ZHAO, De ZHOU, Jianhua HU. Typical hemophagocytic syndrome associated with cytomegalovirus infection in an immunocompetent patient: a case report and literature review[J]. Journal of Zhejiang University Science B, 2023, 24(12): 1159-1164.

@article{title="Typical hemophagocytic syndrome associated with cytomegalovirus infection in an immunocompetent patient: a case report and literature review",
author="Fangfang GENG, Meifang YANG, Xuan ZHANG, Hong ZHAO, De ZHOU, Jianhua HU",
journal="Journal of Zhejiang University Science B",
volume="24",
number="12",
pages="1159-1164",
year="2023",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2300232"
}

%0 Journal Article
%T Typical hemophagocytic syndrome associated with cytomegalovirus infection in an immunocompetent patient: a case report and literature review
%A Fangfang GENG
%A Meifang YANG
%A Xuan ZHANG
%A Hong ZHAO
%A De ZHOU
%A Jianhua HU
%J Journal of Zhejiang University SCIENCE B
%V 24
%N 12
%P 1159-1164
%@ 1673-1581
%D 2023
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2300232

TY - JOUR
T1 - Typical hemophagocytic syndrome associated with cytomegalovirus infection in an immunocompetent patient: a case report and literature review
A1 - Fangfang GENG
A1 - Meifang YANG
A1 - Xuan ZHANG
A1 - Hong ZHAO
A1 - De ZHOU
A1 - Jianhua HU
J0 - Journal of Zhejiang University Science B
VL - 24
IS - 12
SP - 1159
EP - 1164
%@ 1673-1581
Y1 - 2023
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2300232


Abstract: 
Cytomegalovirus (CMV) infection is currently prevalent in populations throughout the world, and 56%‍–94% of the global population is seropositive for CMV. CMV infection mainly affects immunocompromised hosts. In these cases, it can cause significant symptoms, tissue-invasive disease, and many sequelae including death (Dioverti and Razonable, 2016). The vast majority of healthy adults with CMV infection experience an asymptomatic course; when symptomatic, it manifests as a mononucleosis-like syndrome in approximately 10% of patients (Sridhar et al., 2018). The gastrointestinal tract and central nervous system appear to be the most frequent sites of severe CMV infection in immunocompetent individuals (Rafailidis et al., 2008). However, CMV infection is relatively rarely recorded in immunocompetent hosts.

1例芦可替尼成功救治免疫功能正常患者因巨细胞病毒感染导致嗜血细胞综合征的病例报告及文献回顾

耿芳芳1,杨美芳1,张璇1,赵宏1,周德2,胡建华1
1浙江大学医学院附属第一医院感染科,传染病诊治国家重点实验室,国家感染性疾病临床医学研究中心,国家传染病医学中心,感染性疾病诊治协同创新中心,中国杭州市,310003
2浙江大学医学院附属第一医院血液科,中国杭州市,310003
摘要:嗜血细胞综合征是一种罕见的因大量免疫细胞不受控制的激活和增殖以及细胞因子风暴引起的致命性疾病。尽管病毒感染是其常见病因,但由巨细胞病毒引起的嗜血细胞综合征较为少见。巨细胞病毒感染通常可在免疫功能低下或缺陷人群中引起系列疾病,而在免疫功能正常人群中多表现为无症状。本文报道了一例免疫功能正常患者感染巨细胞病毒引起嗜血细胞综合征后,经芦可替尼治疗成功好转。本文旨在强调免疫功能正常患者感染巨细胞病毒后可引起严重的嗜血细胞综合征,而及时给予芦可替尼治疗可以显著改善患者预后。同时,应进一步提高临床医师对免疫功能正常人群感染巨细胞病毒的重视,并为临床工作者提供新的诊疗思路。

关键词:巨细胞病毒感染;嗜血细胞综合征;芦可替尼;免疫能力

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]ChenYH, LeeCH, PeiSN, 2015. Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis. Leuk Lymphoma, 56(5):1528-1529.

[2]DasR, GuanP, SpragueL, et al., 2016. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood, 127(13):1666-1675.

[3]DiovertiMV, RazonableRR, 2016. Cytomegalovirus. Microbiol Spectr, 4:4.

[4]GaoZR, LingXY, ShiCY, et al., 2022. Tumor immune checkpoints and their associated inhibitors. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(10):823-843.

[5]HarrisonC, KiladjianJJ, Al-AliHK, et al., 2012. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med, 366(9):787-798.

[6]HeK, XuSS, ShenLJ, et al., 2022. Ruxolitinib as adjunctive therapy for hemophagocytic lymphohistiocytosis after liver transplantation: a case report and literature review. J Clin Med, 11(21):6308.

[7]HeineA, HeldSA, DaeckeSN, et al., 2013. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood, 122(7):1192-1202.

[8]KeenanC, NicholsKE, AlbeituniS, 2021. Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis. Front Immunol, 12:614704.

[9]MengGQ, WangJS, WangYN, et al., 2021. Successful treatment of cytomegalovirus-induced hemophagocytic lymphohistiocytosis with ruxolitinib as a first-line treatment. Infect Dis Now, 51(3):311-313.

[10]Parampalli YajnanarayanaS, StübigT, CornezI, et al., 2015. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br J Haematol, 169(6):824-833.

[11]RafailidisPI, MourtzoukouEG, VarbobitisIC, et al., 2008. Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. Virol J, 5:47.

[12]RisitanoAM, Peffault de LatourR, 2020. Ruxolitinib for steroid-resistant acute GVHD. Blood, 135(20):1721-1722.

[13]SepulvedaFE, de Saint BasileG, 2017. Hemophagocytic syndrome: primary forms and predisposing conditions. Curr Opin Immunol, 49:20-26.

[14]ShenCH, HwangCE, ChenYY, et al., 2014. Hepatitis B virus reactivation associated with ruxolitinib. Ann Hematol, 93(6):1075-1076.

[15]SridharS, ChungTWH, ChanJFW, et al., 2018. Emergence of cytomegalovirus mononucleosis syndrome among young adults in Hong Kong linked to falling seroprevalence: results of a 14-year seroepidemiological study. Open Forum Infect Dis, 5(10):ofy262.

[16]TongLX, JacksonJ, KerstetterJ, et al., 2014. Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment. J Am Acad Dermatol, 70(3):‍e59-e60.

[17]VannucchiAM, 2015. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med, 372(17):1670-1671.

[18]WangX, DaiCY, YinYF, et al., 2021. Blocking the JAK2/STAT3 and ERK pathways suppresses the proliferation of gastrointestinal cancers by inducing apoptosis. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 22(6):492-503.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2024 Journal of Zhejiang University-SCIENCE